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Abstract
Background: Progesterone, via its nuclear receptor (PR), exerts an overall tumorigenic effect on both uterine fibroid
(leiomyoma) and breast cancer tissues, whereas the antiprogestin RU486 inhibits growth of these tissues through an
unknown mechanism. Here, we determined the interaction between common or cell-specific genome-wide binding sites of
PR and mRNA expression in RU486-treated uterine leiomyoma and breast cancer cells.
Principal Findings: ChIP-sequencing revealed 31,457 and 7,034 PR-binding sites in breast cancer and uterine leiomyoma
cells, respectively; 1,035 sites overlapped in both cell types. Based on the chromatin-PR interaction in both cell types, we
statistically refined the consensus progesterone response element to GNACANNN TGTNC. We identified two striking differences
between uterine leiomyoma and breast cancer cells. First, the cis-regulatory elements for HSF, TEF-1, and C/EBPa and b were
statistically enriched at genomic RU486/PR-targets in uterine leiomyoma, whereas E2F, FOXO1, FOXA1, and FOXF sites were
preferentially enriched in breast cancer cells. Second, 51.5% of RU486-regulated genes in breast cancer cells but only 6.6%
of RU486-regulated genes in uterine leiomyoma cells contained a PR-binding site within 5 kb from their transcription start
sites (TSSs), whereas 75.4% of RU486-regulated genes contained a PR-binding site farther than 50 kb from their TSSs in
uterine leiomyoma cells. RU486 regulated only seven mRNAs in both cell types. Among these, adipophilin (PLIN2), a pro-
differentiation gene, was induced via RU486 and PR via the same regulatory region in both cell types.
Conclusions: Our studies have identified molecular components in a RU486/PR-controlled gene network involved in the
regulation of cell growth, cell migration, and extracellular matrix function. Tissue-specific and common patterns of genome-
wide PR binding and gene regulation may determine the therapeutic effects of antiprogestins in uterine fibroids and breast
cancer.
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Introduction
The steroid hormone progesterone not only plays a central role
in the development, growth, and differentiation of the female
reproductive system, but also is involved in the development and
progression of reproductive diseases, including endometriosis,
endometrial cancer, ovarian cancer, breast cancer, and uterine
leiomyoma [1,2,3,4,5,6]. Studies suggest that breast cancer and
uterine leiomyoma may share some similarities with regard to the
function of progesterone in growth regulation of these tissues
[7,8,9]; however, the effect of progesterone on increasing the risk
for breast cancer and leiomyoma continues to be debated.
Various experimental models have provided seemingly conflict-
ing results. For example, uterine leiomyoma growth is stimulated
by estrogen but not by progesterone in the in vivo Eker rat model
[10]. Yet in vitro, progestin shows similar growth-promoting effects
as estrogen on primary cultures of human uterine leiomyoma cells,
by inhibiting apoptosis and stimulating proliferation [11,12,13].
Most importantly, in an in vivo human leiomyoma xenograft
model, progesterone and its receptor (PR) directly stimulated
growth, whereas the key action of estrogen and its receptor was to
maintain PR expression in leiomyoma tissue [14].
Clinical evidence has suggested that progesterone plays a critical
role in the growth of leiomyoma. Proliferation markers such as Ki67
and proliferating cell nuclear antigen (PCNA) are highest in
leiomyoma in the luteal/secretory phase [15,16,17]. Furthermore,
quantitative proliferation indices of leiomyoma in postmenopausal
women increase significantly with combined estrogen plus progestin
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importantly, antiprogestins such as RU486 (mifepristone) and J867
(asoprisnil) reduce the size of uterine fibroids [18,19].
In breast cancer, both positive and negative effects of progestins on
breast cancer progression have been recapitulated in cellular and
animal models of this disease [20]. In T47D cells, for example,
progestins induce the expression of E2F1 and cyclin D1, facilitate
hyperphosphorylation of Rb, and initiate cell replication [21,22].
When the same cells are implanted in athymic nude mice, robust
progestin-dependent tumor growth is observed [23]. In other cell lines,
such as MCF-7, progestins efficiently inhibit estrogen-dependent cell
proliferation in vitro, an activity that has generally been considered to
underlie their efficacy as breast cancer therapeutics [24].
The antiprogestin RU486 has been shown to prevent mammary
tumorigenesis in mice deficient in tumor suppressors [25].
Clinically, high-dose progestins are occasionally administered to
women with advanced breast cancer to enhance their overall well-
being. In these cases, however, high-dose progestin is not intended
to produce a specific therapeutic effect on breast cancer tissue. The
most definitive evidence that progesterone promotes breast cancer
came from the Women’s Health Initiative Study. Breast cancer
incidence significantly increased in women assigned to the
estrogen plus progestin arm, whereas the risk was surprisingly
lower in those who were taking estrogens alone [26].
These data, combined with known expression patterns of
estrogen receptor alpha (ERa) and PR in breast tumors, suggest a
permissive role of estrogen/ERa, through induction of PR
expression in benign breast tissue or tumors. PR that is liganded
by progesterone or a progestin seems to be the downstream trigger
of tumorigenesis in both uterine leiomyoma and breast cancer
[14,18,25,27,28]. Taken together, this body of evidence highlights
the need to define the roles of progestins, antiprogestins, and their
cognate receptors in reproductive diseases including breast cancer
and leiomyoma, as a first step in the development of strategies to
optimally exploit this signaling axis for the identification of
clinically useful pharmaceuticals.
The genomic activity of progesterone is to a large extent
mediated by the two PR isoforms, PR-A and PR-B, which belong
to the nuclear receptor superfamily of ligand-regulated transcrip-
tion factors (TFs; for a review, see reference [29]). Classically, PR
regulates expression of target genes by binding directly to its
cognate sequence, the progesterone response element (PRE).
Alternatively, nontraditional regulation involves protein-protein
interactions with other DNA-binding proteins such as SP1 and
AP1 [30,31]. Identification of the PR target gene network
regulated by agonists and/or antagonists is essential to gain a
clearer understanding of the role of PR in reproductive tissue
disorders.
Recently, high-throughput ER chromatin immunoprecipitation
sequencing (ChIP-seq) successfully identified a large number of
ER-binding sites in breast cancer cells [30,32,33], which has
transformed our understanding of how ER acts to alter cellular
function. To date, no similar information is available regarding the
genome-wide binding pattern of PR to its downstream genes.
Selective progesterone receptor modulators (SPRM) are partial
progesterone antagonists used for the treatment of breast cancer
and uterine leiomyoma. One of the most widely used is RU486,
which has mixed agonistic/antagonistic properties and tissue-
specific effects [34,35]. SPRMs may have a higher affinity for PR
and induce an alternative conformation of the PR ligand-binding
domain that results in the recruitment of different co-factors and
regulation of gene transcription [36,37,38]. From a translational
perspective, the effect of a SPRM on genome-wide PR binding
and gene expression has not been studied to date.
Here, we took advantage of the observation that RU486 is
therapeutic for two extremely common tumors of women—breast
cancer and uterine leiomyoma—and used massive parallel
sequencing of immunoprecipitated DNA fragments to identify
PR-interaction sites in response to RU486. We coupled this
approach with gene expression profiling to determine common
and tissue-specific mechanisms of RU486 action in both cell types.
Results
Genome-wide binding landscape of PR in breast cancer
T47D and uterine leiomyoma cells
We performed PR ChIP followed by deep sequencing using
breast cancer T47D and human uterine leiomyoma cells that had
been treated with RU486 for 1 hour. We identified 31,457 unique
PR-binding sites in breast cancer cells and 7,034 in leiomyoma
cells. A total of 1,035 binding sites were common to both cell
types, i.e., their locations overlapped (with an average overlap
length of 500 bp) (Figure 1A). ChIP-quantitative PCR analysis
validated the binding of PR to ten representative ChIP-seq peaks
with full or half PREs common to T47D and leiomyoma cells
(Figure 1B). We showed that treatment with RU486 (vs. vehicle
ethanol) significantly enhanced binding of PR to these sites. The
range of RU486-dependent fold-enrichment for ChIP-derived
DNA was 7.1 to 59.4 in T47D cells and 7.3 to 49.8 in leiomyoma
cells. The PR-binding sites in the vicinity of the genes, PLIN2,
BATF, ARRDC1, SERPINA3, and AP2S1, contained half PRE
motifs, whereas those associated with CD82, TNK2, ADNP,
ACSS1, and DDIT4 contained full PRE motifs. These results
suggested that these novel sites are bona fide and functional PR-
binding sites. Furthermore, in comparison with the recently
published 18 PR-binding sites in leiomyoma cells, 12 out of those
18 (66.7%) binding sites were recovered in the present study
including those close to the genes, KLF11, SLC7A8, SLC18A2,
FLT4, RABGGTA, MAN1C1, PLCH2, TRPV3, AP3D1,
LMAN1L, PRDM16 and KIAA1267 [7]. Furthermore, the
current ChIP-seq analysis also confirmed PR binding to a number
of previously known PR-target genes such as MUC1, FKBP5 and
E2F1 [22,39,40].
We compared the locations of PR-binding sites relative to
genomic annotations obtained from the UCSC RefSeq track of the
Human Genome Assembly hg19 [41]. For both cell types, the
number of binding sites per chromosome correlated strongly with
chromosome length, with Pearson correlation coefficients of
r=0.864 for breast cancer cells and r=0.889 for leiomyoma cells
(p,1610
27 for both cell types; Figure 1C). We also noted a
correlation between the number of binding sites and the number
of unique transcription start sites (TSSs) per chromosome:
r=0.713 (p,0.0001) for breast cancer cells and r=0.619
(p,0.002) for leiomyoma cells (Figure 1D).
The distribution of the distances between PR-binding sites and
the closest TSS to a known gene is shown in Figure 1E.
Intriguingly, a higher number of PR-binding sites (5,174; 16.45%
of all binding sites) lay 5 kb proximal (upstream or downstream) to
a TSS in breast cancer cells compared with leiomyoma cells (442
sites; 6.28% of all binding sites). Within the 5 kb region upstream
of a TSS, there was an approximately 3-fold higher likelihood
(10.87% vs. 3.47%) of finding a PR-binding site in breast cancer vs.
leiomyoma cells. In contrast, we found that 47.34% (14,892) of the
PR-binding sites in breast cancer cells and 60.40% (4,249) in
leiomyoma cells were located in regions farther than 50 kb from a
TSS. In agreement with published data on nuclear receptor
binding, 36.7% (breast cancer) and 40.4% (leiomyoma) of the
binding sites were located within an intron [30,42,43]. In general,
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upstream) of a TSS, which may be partially due to the high
intronic occupancy (Table S1). These findings suggest that DNA-
bound PR may interact with the transcriptional machinery
through both proximal- and distal-acting mechanisms.
Transcription factor binding motif analysis of identified
PR-binding sites
With the goal of identifying enriched TF binding motifs in all
PR-binding sites, we scanned their sequences using position weight
matrices (PWMs) from TRANSFAC [44]. For all PWMs from
TRANSFAC, we ranked the enriched motifs in the PR-binding
sites based on their enrichment p-values (See Materials and
Methods; lower p-value means higher rank).
To examine similarities and differences, we assessed the ranking
of enriched motifs (PWMs) and selected the first 100 motifs for
each cell type. Because more than one PWM could map to the
same TF, our results included the TF and its PWMs with
statistically significant hits. The top 10 most common TFs
represented by these subsets are listed in Table 1. Since the
PRE motif is similar to that of the androgen response element
(ARE) and glucocorticoid response element (GRE), it was not
surprising to find that ARE and GRE were highly represented in
this analysis. The remainder of the binding motifs included
HOXA4; LHX2; Msx-1; Otx1,3; Pax-4,6; PITX1; Six-1,2,3,4,6;
and SREBP-1. Among these, only Pax4 binding motifs were
shown to be enriched in glucocorticoid receptor (GR)-binding
sites, suggesting that although GR and PR share a similar binding
motif, they may regulate unique sets of downstream target genes
through interactions with specific TFs [45].
We also identified a number of differences between breast cancer
and leiomyoma cells with respect to enrichment of TF motifs at PR-
binding sites. For example, binding motifs for E2F and Fox family
members, including FOXO1 (FOXO1A), FOXA1 (HNF3A), and
FOXF2 (FREAC2,4), are highly enriched in PR-binding sites in
breast cancer cells but not in leiomyoma cells (Table S2). This is
consistent with previous reports indicating that E2F binding is
enriched in PR target genes, and that FOXA1 binding is enriched in
ER and GR target genes [22,45,46]. On the other hand, we found
that motifs for HSF, TEF-1, and C/EBPaand bwere enriched in PR-
binding sites in leiomyoma cells (Table S3). HSF binding has been
previously reported to be enriched in GR targets, and C/EBP sites
enriched in GR- and ERa-interaction sites [30,45]. Interestingly,
among the top 20 enriched TF binding motifs, we found that AP2 and
SP1 were listed as the two most significantly enriched TFs in breast
cancer cells, whereas AP1 was listed as the top enriched TF in
Figure 1. Summary of PR-binding sites in uterine leiomyoma and breast cancer cells. (A) Venn diagrams summarize the number of PR-
binding sites in T47D breast cancer cells and uterine leiomyoma cells. (B) Validation of in vivo recruitment of PR to novel PR-binding regions identified
by ChIP-seq. T47D and leiomyoma cells (from 5 different subjects) were treated with RU486 (10
26 M) or vehicle (ethanol) for 1 hour. ChIP was
performed using anti-PR or nonspecific rabbit IgG, followed by real-time PCR. Data presented are expressed as fold enrichment of PR relative to IgG,
and are the average of three to five independent ChIP experiments. (C) Correlation between the number of PR-binding sites in an individual
chromosome (X-axis) to the chromosome length (Y-axis). (D) Correlation between the number of PR-binding sites (X-axis) with the number of TSSs (Y-
axis) in an individual chromosome. (E) Distribution of PR-binding sites relative to their nearest TSSs. The percentages of all identified PR-binding sites
in each cell type and region are shown.
doi:10.1371/journal.pone.0029021.g001
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proximal ER or GR targets in various cell types [30,33,47].
Finally, we found that three PREs listed in the TRANSFAC
database were significantly enriched in both cell types (p,1610
212,
Table 2). In leiomyoma cells, 4.8% of PR targets contained the
PR_01 and PR_02 motifs, representing complete PREs; the
frequency of these motifs was approximately 5 times lower in breast
cancer cells (1%). Strikingly, the enrichment of a third motif, which
was a PRE half-site (PR_Q2), was markedly higher than either of
the complete PREs in both breast cancer (28.7%) and leiomyoma
cells (34.8%). These data suggest that PR interacts with half PREs at
a higher frequency than with classical or complete PREs to regulate
downstream target genes in these tissues.
Discovery of de novo motifs in PR-binding sites common
to both cell types
In addition to our analyses guided by PWMs from TRANS-
FAC, we attempted to identify new motifs in PR targets common
to both breast cancer and leiomyoma cells using MEME as the
motif discovery tool [48]. We compared the discovered motifs to
known motifs from the TRANSFAC and JASPAR databases [49].
Figure 2 shows the three discovered motifs and their TRANS-
FAC counterparts. There were some similarities between the
discovered motifs and the three known PREs from TRANSFAC
(p,5610
25). We noted, however, novel and unique features that
were common to all three discovered motifs. There was a clear
preference for a G in positions 1 and 10, an A in positions 3 and 5, a
C in positions 4 and 13, and a T in positions 9 and 11. Based on the
discovered sequences from our genome-wide PR binding data, we
propose the following revised consensus PRE: GNACANNNTGTNC
(Figure 2D). This 13 bp revised motif adheres to the classical
consensus frame comprised of two palindromic repeats separated by
interchangeable 6th, 7th, and 8th spacer nucleotides. Here, we
found that adenines and thymidines at the 2nd and 12th bp
positions are highly variable and possibly dispensable.
An analysis of the top five discovered motifs with the highest
similarity to a known motif in the TRANSFAC or JASPAR
databases identified UF1-H3b, SP-1, AR, Krox, and ZFP281
binding motifs (Figure S1). The UF1-H3b motif is a sequence in
Table 1. Top 10 enriched TF binding motifs within PR-binding sites common to both T47D breast cancer cells and leiomyoma
cells.
Breast cancer Leiomyoma
Factor name Description
TRANSFAC
matrix ID Z-value p-value Z-value p-value
AR Androgen receptor; NR3C4 V$AR_01 54.723 ,1.0e-323 90.819 ,1.0e-323
V$AR_04 51.514 ,1.0e-323 77.330 ,1.0e-323
GR Glucocorticoid receptor; NR3C1 V$GRE_C 36.067 1.3e-280 58.241 ,1.0e-323
HOXA4 HOX1D V$HOXA4_Q2 244.989 ,1.0e-323 213.617 2.0e-038
LHX2 hLH-2; LH-2 V$LH2_01 244.113 ,1.0e-323 212.073 8.3e-030
Msx-1 Msh homeobox 1; MSX1 V$MSX1_02 255.425 ,1.0e-323 212.930 1.9e-034
Otx 1,3 Diencephalon/mesencephalon homeobox 1; V$OTX1_01 252.433 ,1.0e-323 218.657 9.7e-074
Dmbx1 V$OTX3_01 250.794 ,1.0e-323 217.122 8.2e-062
Pax- 4,6 Paired box genes 4 and 6; PAX4; PAX6 V$PAX4_02 250.005 ,1.0e-323 218.592 3.3e-073
V$PAX6_02 241.860 ,1.0e-323 210.909 5.4e-024
PITX1 Pituitary homeobox 1; Ptx1 V$PITX1_01 251.469 ,1.0e-323 220.052 1.8e-085
Six- 1,2,3,4,6 SIX homeobox 1, 2, 3, 4, and 6; Six1; Six3; V$SIX1_01 243.183 ,1.0e-323 214.400 3.5e-043
Six6; Six9 V$SIX2_01 241.374 ,1.0e-323 214.115 2.0e-041
V$SIX3_01 242.943 ,1.0e-323 214.693 4.9e-045
V$SIX4_01 238.304 ,1.0e-323 216.814 1.5e-059
V$SIX6_01 244.116 ,1.0e-323 213.853 7.9e-040
V$SIX6_02 241.634 ,1.0e-323 213.432 2.5e-037
SREBP-1 Sterol regulatory element binding protein 1 V$SREBP1_01 238.048 ,1.0e-323 214.936 1.4e-046
doi:10.1371/journal.pone.0029021.t001
Table 2. Enriched PREs at PR targets in T47D breast cancer cells and leiomyoma cells.
Breast cancer Leiomyoma Common to the two cells
Motif
Number of binding sites
including the motif (%) p-value
Number of binding sites
including the motif (%) p-value
Number of binding sites
including the motif (%) p-value
PR_01 108 (0.3%) 6.8e-017 124 (1.8%) ,1.0e-323 23 (2.2%) 3.0e-103
PR_02 204 (0.7%) 8.6e-049 208 (3.0%) ,1.0e-323 39 (3.8%) ,1.0e-323
PR_Q2 9,020 (28.7%) 1.7e-013 2,444 (34.8%) 1.7e-041 225 (21.7%) 3.6e-026
doi:10.1371/journal.pone.0029021.t002
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binding protein [50]; the Krox element has been found in the
human tumor necrosis factor promoter [51]; and ZFP281 binds to
the G-rich box in the enhancer region of ornithine decarboxylase,
an essential enzyme for cell growth [52].
Characterization of genes with TSSs within 50 kb of a PR-
binding site
We performed KEGG molecular pathway enrichment analysis
on three sets of genes. The first two sets, one for breast cancer and
one for leiomyoma, contained genes whose TSS was located within
50 kb ofa PR-bindingsite ineachcelltype. The third setfocused on
genes with TSSs within 50 kb of any of the PR-binding sites that
were common to both cell types. Our goal was to determine the
functional associations of genes within 50 kb of a PR-binding site.
Of the genes with PR-binding sites common to both cell types,
several KEGG pathways were overrepresented, including those of
focal adhesion, regulation of actin cytoskeleton, neurotrophin
signaling, ErbB signaling, various cancer pathways, and insulin
signaling (Table 3).
Figure 2. Sequence logos of PRE consensus motifs. The three known PRE motifs from TRANSFAC are shown in upper panels A (PR_01), B
(PR_02), and C (PR_Q2). The consensus logo motifs derived using MEME analysis of ChIP-seq data from the 1,035 PR-binding sites common to both
T47D breast cancer cells and leiomyoma cells are shown in lower panels of A, B, and C. Panel D shows the proposed consensus PRE motif based on
the three TRANSFAC motifs and the discovered motifs from ChIP-seq data. For the consensus logos, the vertical axes (Bits) indicate the information
content of the base frequency at that position. The horizontal axes refer to consensus site position.
doi:10.1371/journal.pone.0029021.g002
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also identified several KEGG pathways that were unique to each
cell type. In T47D breast cancer cells, pathways involving
endocytosis, ubiquitin mediated proteolysis, mTOR signaling,
Wnt signaling, and apoptosis were specifically overrepresented
(Table 3). On the other hand, pathways involving extracellular
matrix (ECM)-receptor interaction, Fc gamma R-mediated
phagocytosis, Jak-STAT signaling, glioma, and hypertrophic
Table 3. KEGG pathways enriched in genes with TSSs located within 50 kb of a PR-binding site.
KEGG ID Name p-value FDR
Pathways enriched in both cell types
4510 Focal adhesion 2.1e-04 5.9e-03
4810 Regulation of actin cytoskeleton 7.1e-05 4.6e-03
4722 Neurotrophin signaling pathway 8.8e-04 1.2e-02
5215 Prostate cancer 1.7e-04 6.1e-03
5220 Chronic myeloid leukemia 1.5e-03 1.6e-02
4012 ErbB signaling pathway 3.3e-04 7.4e-03
4670 Leukocyte transendothelial migration 1.3e-03 1.5e-02
5200 Pathways in cancer 8.3e-04 1.0e-02
5211 Renal cell carcinoma 9.0e-04 1.2e-02
4910 Insulin signaling pathway 1.0e-03 1.0e-02
5221 Acute myeloid leukemia 5.2e-03 4.4e-02
5222 Small cell lung cancer 1.6e-03 1.6e-02
5212 Pancreatic cancer 3.4e-03 2.3e-02
4520 Adherens junction 6.9e-03 4.0e-02
Pathways enriched in T47D breast cancer cells only
4144 Endocytosis 3.2e-06 4.4e-04
4120 Ubiquitin-mediated proteolysis 4.5e-06 4.4e-04
4150 mTOR signaling pathway 1.8e-04 5.8e-03
0603 Glycosphingolipid biosynthesis - globo series 5.2e-04 1.0e-02
4360 Axon guidance 7.0e-04 1.2e-02
4530 Tight junction 1.1e-03 1.3e-02
4310 Wnt signaling pathway 3.4e-03 3.4e-02
4210 Apoptosis 3.6e-03 3.4e-02
0512 O-glycan biosynthesis 4.0e-03 3.6e-02
1100 Metabolic pathways 5.5e-03 4.5e-02
Pathways enriched in leiomyoma cells only
4512 ECM-receptor interaction 1.3e-07 1.2e-05
4666 Fc gamma R-mediated phagocytosis 2.5e-04 7.3e-03
4630 Jak-STAT signaling pathway 4.2e-04 7.6e-03
4960 Aldosterone-regulated sodium reabsorption 7.2e-04 1.0e-02
4070 Phosphatidylinositol signaling system 9.5e-04 1.0e-02
5214 Glioma 1.0e-03 1.0e-02
0562 Inositol phosphate metabolism 1.0e-03 1.0e-02
5223 Non-small cell lung cancer 1.0e-03 1.0e-02
5410 Hypertrophic cardiomyopathy (HCM) 1.6e-03 1.4e-02
5213 Endometrial cancer 2.1e-03 1.7e-02
4662 B-cell receptor signaling pathway 2.1e-03 1.7e-02
5218 Melanoma 2.9e-03 2.1e-02
4010 MAPK signaling pathway 2.9e-03 2.1e-02
4062 Chemokine signaling pathway 3.7e-03 2.5e-02
5414 Dilated cardiomyopathy 4.3e-03 2.8e-02
5412 Arrhythmogenic right ventricular cardiomyopathy (ARVC) 6.0e-03 3.8e-02
4660 T-cell receptor signaling pathway 6.4e-03 3.9e-02
doi:10.1371/journal.pone.0029021.t003
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cells (Table 3). These data suggest that distinct pathways can be
activated by an antiprogestin and PR in a cell-specific manner.
Genes regulated by RU486 in breast cancer and
leiomyoma cells
To correlate RU486-induced PR binding with RU486-
mediated gene regulation, we performed microarray gene profiling
assays of T47D breast cancer cells and primary leiomyoma cells
treated with RU486 or vehicle for 6 hours. We identified 230
downregulated and 145 upregulated genes in response to RU486
treatment in breast cancer cells (Figure 3A), whereas RU486
treatment downregulated 32 and upregulated 29 genes in
leiomyoma cells (Figure 3B). Complete lists of these genes are
presented in Tables S4 (breast cancer cells) and S5 (leiomyoma
cells). RU486 regulated seven genes in both cell types: prothymo-
sin alpha (PTMA), SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily a member 1
(SMARCA1), capping protein (actin filament) muscle Z-line alpha
1 (CAPZA1), perilipin 2 (PLIN2), poly(A)-binding protein
cytoplasmic 1 (PABPC1), annexin A2 pseudogene 1 (ANXA2P1),
and tryptophan-rich basic protein (WRB). RU486 upregulated
PLIN2 and downregulated the rest of these genes in both cell
types. Except for ANXA2P1 and WRB, which have unknown
functions, all of these genes have been reported to play important
roles in cellular function [53,54,55]. For example, PTMA, a
downstream target gene of estrogen, encodes an oncoprotein
associated with cell proliferation and chromatin remodeling [56].
SMARCA1, a chromatin remodeling gene, has been reported to
stimulate steroidogenic acute regulatory (StAR) protein expression
through association with the StAR promoter, and SMARCA1
knockdown causes significant growth inhibition and induces
apoptosis of cancer cells [57,58].
The distribution of PR-binding sites relative to the nearest TSS
of RU486-regulated genes is shown in Figure 3C for the T47D
breast cancer cells and Figure 3D for leiomyoma cells. A striking
difference was observed between the two cell types. In breast
cancer cells, the majority of the differentially regulated genes
(51.47%) contained a PR-binding site within 5 kb up- or
downstream of their TSSs. In contrast, the majority of the
RU486-regulated genes (75.41%) in leiomyoma cells had a PR-
binding site more than 50 kb away from the TSSs. To further
Figure 3. Correlation between RU486-induced PR-binding and RU486-mediated gene expression. Venn diagrams summarize the
number of RU486-mediated genes with identified PR-binding sites within 5 kb from their TSSs in breast cancer cells (A) and leiomyoma cells (B).
Distribution of PR-binding sites relative to TSSs of differentially expressed genes in T47D breast cancer cells (C) and uterine leiomyoma cells (D). T47D
and leiomyoma cells were treated with vehicle (ethanol) or RU486 (10
26 M) for 6 hours and expression profiling was performed using Human HT-12
v4 Expression BeadChip arrays from Illumina. The percentage of all differentially regulated genes with PR-binding sites in each region is shown in the
vertical axis. The distance relative to the TSS is shown in the horizontal axis.
doi:10.1371/journal.pone.0029021.g003
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between the two cell types, we examined the genomic regions
located 5 kb up- and downstream of the TSSs of differentially
expressed genes. In breast cancer cells, 43.9% of downregulated
genes and 63.4% of upregulated genes contained PR-binding sites
within 5 kb from their TSSs (Figure 3C). This finding indicates the
significant enrichment of PR-binding sites in genomic regions
proximal to the TSSs of RU486-regulated genes in breast cancer
cells. In contrast, only 10.3% of upregulated and 3.1% of
downregulated genes contained PR-binding sites within 5 kb of
their TSSs in leiomyoma cells (Figure 3D). Taken together, these
findings indicate the presence of distinct mechanisms that regulate
RU486/PR action in breast cancer cells vs. leiomyoma cells.
RU486/PR-mediated regulation in breast cancer cells favors
proximal regulatory elements, whereas distal enhancer elements
are used more often in leiomyoma cells.
RU486 regulates PLIN2 expression in a dose- and time-
dependent manner
We selected the PLIN2 gene that encodes adipophilin to
validate its regulation by RU486. PLIN2 contains PR-binding sites
that overlap with its TSS, and we showed that it was upregulated
by RU486 in both cell types. PLIN2 plays key roles in lipid droplet
formation and milk formation and secretion [59,60]. High PLIN2
expression is associated with better cancer-free survival in clear cell
renal carcinoma [61]. PLIN2 is also involved in the regulation of
fibrotic genes, including the suppression of collagen I and matrix
metalloproteinase-2 mRNA levels and stimulation of matrix
metalloproteinase-1 mRNA levels [55].
As shown in Figure 4A and 4B, we used real-time PCR to verify
the changes in PLIN2 mRNA that we observed in our microarray
analysis. RU486 (10
26 M) treatment for 6 hours increased PLIN2
expression in T47D breast cancer cells and leiomyoma cells. To
analyze the dose response of PLIN2 expression to RU486
treatment in both cell types, various concentrations (10
29 to
10
25 M) of RU486 or vehicle (ethanol) were added to the medium
for 6 hours. The greatest induction in PLIN2 expression was
observed at 10
27 M RU486 in T47D breast cancer cells and
10
25 M RU486 in leiomyoma cells (Figure 4C and 4D). To
explore the temporal response of PLIN2 expression to RU486
stimulation, both cell types were treated with 10
26 M of RU486
for 1, 3, 6, or 24 hours. RU486 stimulated PLIN2 mRNA levels as
early as 6 hours, and increased throughout the 24 hour treatment
time point in both cell types (Figure 4E and 4F).
Discussion
Progesterone is extraordinarily important to normal reproduc-
tive function, and acts as a master regulator to control
implantation, maintenance of pregnancy, and breast development,
as well as inhibit endometrial carcinogenesis. Progesterone has also
been implicated in the promotion of growth of breast cancer and
uterine leiomyoma. The anti-progestin RU486 inhibits both breast
cancer and uterine leiomyoma growth and thus represents a
potential therapeutic for these reproductive diseases.
ChIP-seq has been used successfully to identify genome-wide
ER- and GR-binding sites [30,32,33], yet no such literature is
available for PR despite the important and complex effects of
progesterone on the female reproductive tract. To unravel the
target gene network of a particular TF, in this case PR, the
identification of interaction sites, cis-regulatory elements, and
target genes is essential. Therefore, we applied ChIP-seq to
identify PR-interaction sites in T47D breast cancer cells and
primary uterine leiomyoma cells treated with RU486. Using a
relatively stringent analytic approach, we found 31,457 PR-
binding sites in breast cancer cells and 7,034 in leiomyoma cells,
with 1,035 PR-binding sites that overlapped between the two cell
types. Microarray gene profiling analyses found seven genes
commonly regulated by RU486 in both cell types. Based on the
function of these genes and the same direction of the regulation,
these findings provide insight into the mechanisms underlying the
observed clinical effects of RU486 treatment in these diseases.
Using cell-free assays or transfection of gene reporter constructs,
the consensus sequence for binding of GR, PR, AR, and MR
(mineralocorticoid receptor) has been predicted to be an inverted
repeat with a three-nucleotide spacer region: AGAACAnnn-
TGTTCT, where the underlined nucleotides are most important
for receptor binding [62]. Using insertion and substitution of the
PRE core sequence in the mouse mammary tumor virus promoter
in in vitro PR binding assays, Lieberman et al proposed an optimal
PR binding motif as 27RGNACANRNTGTNCY+7 [63]. Here,
we report the first in situ determination of a consensus PRE based
on ChIP-seq data from 1,035 PR-binding sites in both breast
cancer and leiomyoma cells: GNACANNNTGTNC, which is consistent
with the two previously reported motifs. The finding that the
independently determined consensus sequence from the ChIP-seq
data closely matched the previously defined optimal binding sites
for PR supports the biological relevance of our ChIP-seq results.
In addition to the classical complete PRE, PR has also been
reported to regulate gene transcription through interaction with
half PRE sites [39]. Supporting this notion, we found that genome-
wide PR targets contained strikingly higher numbers of half PREs
compared with full length PRE motifs. It has been demonstrated
that the magnitude of estrogen-dependent recruitment of ER to
binding sites containing canonical full EREs is stronger than
recruitment to sites containing half-EREs [33]. It will be
interesting to clarify whether PR has the same characteristics.
The mechanisms by which endogenous PR prefers to bind half
PRE are unknown. Thus far, we cannot exclude the possibility
that the abundance of half PRE sites in native chromatin is much
higher than that of full PRE sites.
Interestingly, de novo motif analysis identified UF1-H3b as one
of the most highly enriched motifs among genome-wide PR-
binding sites. Although it is not clear what TF binds to this
sequence, the UF1-H3b motif is also overrepresented in the
promoters of direct targets of FOXA2. It has been reported in M.
musculus that proximal UF1-H3b and SP-1 binding sites are
involved in repressing FOXA1 promoter activity [64]. The
functional importance of the enrichment of this motif in PR-
binding sites is unclear.
In line with observations that PR physically and/or functionally
interacts with other TFs, we revealed that, among others, the FOX
family member motifs are specifically enriched at PR targets in
breast cancer cells, whereas HSF, TEF-1, and C/EBP motifs are
overrepresented in leiomyoma cells, suggesting that through
interaction with those TFs, PR may produce cell-specific effects.
Others have reported that FOXA1 is enriched in binding sites of
ER and GR, substantiating the notion that this TF may be a key
factor that coordinates with nuclear receptors of steroid hormones
to regulate their downstream gene targets [22,45,46]. Among the
top 20 TF binding motifs enriched at genome-wide PR targets, we
found that AP2 and SP1 sites were the most frequent motifs in
breast cancer cells, whereas AP1 was the most frequent motif in
leiomyoma cells. Given that these motifs bind common TFs that
interact with PR in the absence of a PRE, the mechanism
underlying the cell-specific preference of their usage is unknown.
In breast cancer cells and leiomyoma cells, we found that PR
interaction sites significantly overlapped. Many of the genes
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migration, metabolic processes, and biosynthetic processes (Yin P
and Bulun SE, unpublished data), and affect pathways includ-
ing ErbB and insulin signaling, as well as pathways in cancer.
Through KEGG pathway enrichment analysis, we also identified
several pathways uniquely enriched in each cell type, suggesting
that PR may exert specific functional effects on each disease. In
breast cancer, which is characterized by rapid growth, invasion,
and metastasis, PR was associated with pathways involving
mTOR and Wnt signaling and apoptosis. In contrast, leiomyoma
cells are characterized by slow growth and overproduction of
ECM proteins, and PR may specifically affect the interaction
between cell surface receptors and ECM elements in this tissue.
Consistent with earlier studies [7,30,42,43], a small fraction of
PR-interaction sites were located in promoter regions, whereas the
majority of sites was found at large distances from annotated genes
or within introns. These distal sites most likely act as enhancers
and interact with receptive promoters through looping to regulate
gene expression, as has been described for PR target genes such as
E2F1 and KLF11, and ERa target genes such as TFF1, GREB1,
and bcl-2 [7,22,65,66,67].
Compared with leiomyoma cells, RU486 treatment of T47D
breastcancer cellsinducedanotablyhigher number of genome-wide
PR interaction sites and differentially regulated mRNA species.
These observations may be partially due to the significantly higher
PR protein level in T47D breast cancer cells than in leiomyoma cells
(Yin P and Bulun SE, unpublished data). Moreover, the amount of
chromatin material that can potentially interact with PR is higher in
T47D cells, which have 66 chromosomes rather than the usually
normal karyotype of leiomyoma cells [68].
Figure 4. Effect of RU486 treatment on the expression of PLIN2. Expression of PLIN2 by real-time PCR in breast cancer T47D (A) and primary
uterine leiomyoma cells (B). Serum-starved T47D or leiomyoma cells were stimulated with variable concentrations of RU486 (ranging from 10
29 to
10
25 M) or vehicle for 6 hours (C and D), or RU486 (10
26 M) or vehicle for 1, 3, 6, or 24 hours (E and F). PLIN2 mRNA levels were normalized to GAPDH
expression. Results are reported as fold change compared with cells treated with vehicle only and represent the mean 6 SEM of three independent
experiments. Reference: star symbol, p,0.05 compared with vehicle treatment.
doi:10.1371/journal.pone.0029021.g004
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specific DNA sequences in the regulatory regions of genes. Our
data provides the first evidence that there is a cell-type specific
preference in the usage of proximal regulatory regions vs. distal
enhancer regions in the regulation of gene transcription by PR. In
T47D breast cancer cells, 51.47% of RU486-regulated genes
contained a PR-binding site within 5 kb up- or downstream from
their TSSs, whereas PR binding proximal to a TSS was associated
with only 6.56% of RU486-regulated genes in leiomyoma cells.
One explanation for this cell-type specific preference is that the
receptors interact or cooperate with other TFs and that this
cooperation may be in part determined by the availability of these
TFs in the specific cell type. In addition, the local chromatin
landscape and histone modifications in each cell type are likely to
play decisive roles in gene regulation, as has been described for
GR [69].
It has been reported that the majority of estrogen-activated
genes are associated with one or more ERa-binding sites,
indicating that ERa complexes bound to multiple interaction sites
probably cooperate to regulate expression of diverse target
genes such as TCF4 and MYC [70,71]. PR may use the same
mechanisms to mediate its target gene expression. Nevertheless,
the requirement of multiple PR-binding sites per RU486-regulated
gene alone cannot account for the extreme discordance between
the number of RU486-regulated genes (375) and PR-binding sites
(31,457) in T47D cells, and the number of RU486-regulated genes
(61) and PR-binding sites (7,034) in leiomyoma cells. This is
exemplified in Figure 1B showing PR-binding activity in close
proximity to ten genes, only four of whose mRNA levels are
regulated by RU486 in breast cancer cells. It appears that the
dispersed and often distal localization of PR-binding sites
complicates the assignment of PR-interaction sites to RU486-
responsive genes.
More importantly, mRNA levels do not necessarily reflect gene
activity because transcripts are subject to degradation and
regulation, and not all PR-binding sites are likely to be active
under all conditions. In this case, genome-wide profiling of RNA
polymerase II occupancy might provide a much more direct
readout and could yield insights beyond what is typically obtained
by mRNA expression profiling [30]. Also, the inherent differences
between analyses based on PR occupancy and on mRNA levels
cannot be ignored.
In conclusion, our study provides novel and important insights
into the regulation of the PR target gene network and serves as a
resource for the further elucidation of PR-regulated transcription
in T47D and leiomyoma cells. Our findings may directly inform
the development of common and disease-specific treatment
strategies for human breast cancer and uterine leiomyoma.
Materials and Methods
Ethics Statement
To obtain human tissues, we followed the protocol approved by
the Institutional Review Board for Human Research of North-
western University. Written informed consent was received from
all subjects.
Tissue collection and cell culture
Human uterine leiomyoma tissues were obtained at surgery
from 20 premenopausal women (mean age 40 years, range 33–48).
The subjects had not received any hormonal treatment during the
six months prior to surgery. The size of the tumors varied between
3.5 to 10 cm and their location was predominantly intramural.
Primary leiomyoma cells were cultured as previously described
[72]. Cells used in these experiments were passaged one or two
times. T47D breast cancer cells were kindly provided by Dr.
Frasor J (University of Illinois at Chicago) and were cultured as
previously described [73].
ChIP-seq
T47D or leiomyoma cells treated with RU486 for 1 hour were
fixed with 1% formaldehyde for 15 min and quenched with
0.125 M glycine. Chromatin was isolated by adding lysis buffer,
followed by disruption with a Dounce homogenizer. Lysates were
sonicated and the DNA sheared to an average length of 300–
500 bp. Genomic DNA was prepared by treating aliquots of
chromatin with RNase, proteinase K and heat for de-crosslinking,
followed by ethanol precipitation. Pellets were resuspended and
the resulting DNA was quantified on a NanoDrop spectropho-
tometer. Extrapolation to the original chromatin volume allowed
quantitation of the total chromatin yield.
An aliquot of chromatin (30 mg) was precleared with protein G
agarose beads (Invitrogen). Genomic DNA regions of interest were
isolated using 4 mg antibody against PR (sc-7208, Santa Cruz
Biotechnology). Complexes were washed, eluted from the beads
with SDS buffer, and subjected to RNase and proteinase K
treatment. Crosslinks were reversed by incubation overnight at
65uC, and ChIP DNA was purified by phenol-chloroform
extraction and ethanol precipitation.
We followed the procedures for preparing the Illumina genomic
DNA library for sequencing, and the resulting DNA from the
leiomyoma and T47D cells was sequenced separately on the
Illumina Genome Analyzer 2 (Illumina, Inc.). The identified 35-nt
sequence reads were mapped to the NCBI GRCh37 assembly of
the human genome using the Solexa GAPipeline and the ELAND
standalone program [http://www.illumina.com/software/genome_
analyzer_software.ilmn#casava]. Only reads that mapped uniquely,
had no more than two mismatches, and passed quality control
filtering were considered. The enriched binding sites were identified
with the Model-based Analysis of ChIP-seq Algorithm (MACS) [74].
MACS models the distribution of tags across the genome with a
Poisson distribution obtained from the control sample. Because the
experiment does not have a control dataset, the background
distribution of tags was modeled using the reads in the ChIP-seq
samples. The tag size was set at 36 nt and the bandwidth was set to
130 nt. A conservative p-value of 10
211 was used to call peaks. In
order to keep the false discovery rate (FDR) low, and because of the
absence of a control sample, no global lambda was used.
Mapping genes adjacent to PR-binding sites
To determine the association of PR-binding sites with genes, we
computed the distance of each binding site to the closest TSS.
Genomic locations were obtained for all gene transcripts in the
UCSC RefSeq track of the latest Human Genome Assembly:
hg19/GRCh37 [41]. Distance between a binding site and a
transcript’s TSS was computed using the bindSDb database,
which takes into consideration the strand orientation [75]. The
minimum distance between a PR binding site and a TSS was used
to determine association between the gene and the binding site.
Validation of the in vivo PR-binding sites by ChIP-real
time PCR
Standard ChIP assays followed by real-time PCR were used to
validate ten PR-binding sites identified by ChIP-seq. T47D or
leiomyoma cells were treated with RU486 (10
26 M) or vehicle
(ethanol) for 1 hour. DNA after ChIP of PR and IgG (ab46540,
Abcam Inc.) as well as input DNA were analyzed by real time
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Primers were generated corresponding to the regions within
each ChIP-seq derived genomic fragment. Their sequences are
available upon request. The RU486-mediated fold enrichment of
PR-binding regions relative to IgG was compared with its vehicle
control.
Motif search
All PR-binding sites were resized to a length of 1,000 bp
(500 bp to the left and right of the peak) and their nucleotide
sequences were obtained from the UCSC hg19 genome assembly.
These sequences were analyzed to identify common motifs using
two different approaches: (1) a search for known motifs using
position weight matrices (PWMs) and (2) de novo discovery of
motifs.
Motif search using PWMs. All PR-binding sites were
scanned with the MATCH software using the PWMs from
TRANSFAC (ver. 2010.1) [44,76]. The set of thresholds labeled as
‘‘Minimize False Positive’’ was used to identify putative TF
binding sites. To evaluate the significance of motif enrichment, we
compared the enrichment of that motif against a set of background
sequences. For each PR-binding site, a background site of the
same length was created from its vicinity (within a random
distance of 1 to 10 kb up- or downstream and not overlapping
with any other true PR-binding site). The nucleotide sequences for
each of these background sites were obtained. Then, as it was
performed for the PR-binding sites, each PWM from TRANSFAC
was scanned in the background sites using the MATCH algorithm
and the ‘‘Minimize False Positive’’ set of thresholds. The choice of
using true DNA sequences for our background set, as opposed to
synthetic ones, was based on our goal to have a better model of
binding affinity for PWMs.
For each PWM, the proportion of nucleotides from the true
binding sites that contained a reported hit of that PWM was
obtained and compared with the proportion of nucleotides in
background sites that also contained a hit. For a large sample size,
the central limit theorem indicates that the distribution of the
sample proportion is approximately normally distributed. There-
fore, a z-value was computed for a PWM according to formula (1):
z~
pt{pb ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pb(1{pb)
n
r ð1Þ
where:
pt is the proportion of nucleotides from true PR-binding
sites where the PWM scored a hit.
pb is the same proportion as above but for nucleotides in
the background sites.
n is the total number of nucleotides (number of binding
sites6length of binding sites).
Based on the z-value for each PWM, the p-value was computed
and adjusted for multiple hypotheses testing using the Bonferroni
correction.
Progesterone receptor PWM (motif). TRANSFAC [44]
normally has one or more PWMs to evaluate the binding affinity
of one TF. In the case of PR, there are three different PWMs:
PR_02, progesterone receptor; PR_01, obtained from high affinity
binding sites; and PR_Q2, the half-site PRE. In our motif analysis,
a binding site was considered to have a PR motif if MATCH
reported at least one hit for any one of the three PWMs.
De novo discovery of motifs. In addition to the enrichment
analysis with PWMs, a motif discovery analysis using MEME was
conducted [48]. We focused only on the PR-binding sites that
were common to both cell types. Numerous scans on these sites
were run, changing the width of the target motif from 8 to 23, and
looking not only at the target sequence, but also at its reverse
complement. For each run, the top 20 motifs were selected (based
on their p-values). The output of all the runs was then consolidated
using the motif comparison tool Tomtom [77]. Tomtom takes a
query motif, compares it to a target motif, and provides a statistical
measure (p-value) of how similar they are compared to a null
model. When the query is compared to multiple targets, the p-
value is corrected for multiple hypotheses testing, thereby yielding
an E-value. A third metric, called a q-value, measures the minimum
FDR necessary to report the match between the motifs. In our
analysis, when multiple discovered motifs had high similarity to a
known TRANSFAC or JASPAR [49] motif, the one with the lowest
E-value was kept. The q-value was used to rank all matches.
Gene functional annotation analysis
Gene set enrichments of KEGG pathways were determined
using hypergeometric tests. Two sets of genes were analyzed for
KEGG enrichment: genes whose TSS was located within 50 kb of
PR-binding sites in T47D cells, genes whose TSS was located
within 50 kb of PR-binding sites in leiomyoma cells. A hypergeo-
metric test was performed on each set to determine overrepre-
sentation in KEGG pathways. The gene universe for the KEGG
pathways was 5,501 genes uniquely identified by Entrez ID and
with the condition of having at least one KEGG pathway
associated with them. The enriched KEGG pathways in each
set with FDR less than 0.05 were reported. The analysis was
implemented with the GOstats package in Bioconductor.
When listing in Table 3 the pathways that were enriched in both
hypergeometric tests, the largest p-value and FDR values, for each
pathway, were reported.
Microarrays and data analysis
Total RNA was isolated from T47D or leiomyoma cells treated
with vehicle (ethanol) or RU486 (10
26 M) for 6 hours. Expression
profiling was performed using HumanHT-12 v4 Expression
BeadChip arrays from Illumina (Illumina, Inc.) following the
protocol described previously [78]. For each cell type, six
microarrays were processed: three vehicle and three treated
samples. After quality control, three of the samples were discarded
from further analysis (one vehicle and one treatment for T47D
cells, and one treatment for leiomyoma cells). The raw expression
data were normalized using the Robust Spline Normalization
(RSN) algorithm implemented in the lumi package in Bioconduc-
tor [79]. Only the probes with a present call were considered for
the analysis. The differentially expressed probes were determined
by the fold change (FC) of expression level in RU486 treated vs.
control. The FC threshold was set to 61.40 for T47D cells and
61.30 for leiomyoma cells. Finally, probes were mapped to genes
using the nucleotide universal Identifier (nuID) annotation. The
microarray data is MIAME compliant and is available at the Gene
Expression Omnibus Web site (http://www.ncbi.nlm.nih.gov/
geo) under accession number GSE30871.
Real-time quantitative PCR
Total RNA from T47D and leiomyoma cells was extracted
using Tri-reagent (Sigma-Aldrich). Complementary DNA was
prepared with Superscript III first-Strand Synthesis System
(Invitrogen). PLIN2 and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) mRNA were amplified by real-time PCR using
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were: GAPDH: forward: 59-GAAGGTGAAGGTCGGAGTC-39;
reverse: 59-GAAGATGGTGATGGGATTTC-39; PLIN2: for-
ward: 59-AGTATCCCTACCTGAAGTCTGTG-39; reverse: 59-
CCCCTTACAGGCATAGGTATTG-39. All gene expressions
were normalized to GAPDH.
Statistical analysis
The Fisher’s exact test was used to test the enrichment of PR-
binding sites in proximity of genomic regions of TSSs for the
differentially expressed genes. Differences between groups were
analyzed by Student’s t test or one-way ANOVA analysis followed
by Fisher’s protected least significance difference test. Significance
was accepted at p,0.05.
Supporting Information
Figure S1 De novo search of cis-regulatory motifs
enriched within PR-binding sites. MEME analysis identified
putative motifs for other TFs in ChIP-seq data from the 1,035 PR-
binding sites common to both T47D breast cancer cells and
leiomyoma cells. The top five motifs (lower panels) with the highest
similarity to a known motif in TRANSFAC or JASPAR (upper
panels) are shown in A, B, C, D, and E. Vertical axes (Bits) indicate
the information content of the base frequency at that position. The
horizontal axes refer to consensus site position.
(TIF)
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